Idiopathic Multicentric Castleman Disease (iMCD): CDCN 2017 Criteria, TAFRO Variant, and Siltuximab First-Line Therapy

Idiopathic Multicentric Castleman Disease (iMCD): CDCN 2017 Criteria, TAFRO Variant, and Siltuximab First-Line Therapy

A comprehensive guideline to navigating the CDCN 2017 international consensus diagnostic criteria, recognizing the TAFRO and NOS-IPL subtypes, identifying IL-6-driven systemic inflammation, and selecting siltuximab as first-line anti-IL-6 therapy.

By gomdori · Hematology · 13 minute read

Executive Summary

Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by multicentric lymphadenopathy with characteristic hyaline-vascular or plasma cell histology, multi-organ inflammation driven by IL-6 hypersecretion in many patients, and frequent constitutional symptoms with cytopenias, organomegaly, and effusions. The Castleman Disease Collaborative Network (CDCN) 2017 international consensus diagnostic criteria formalize the diagnosis requiring excisional lymph node biopsy, multicentric distribution, at least 2 of 11 minor criteria (laboratory and clinical), HHV-8 negativity by LANA-1 immunohistochemistry, and exclusion of alternative diagnoses. Two distinct iMCD subtypes are now recognized: iMCD-TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, Organomegaly) representing a severe acute syndrome, and iMCD-NOS (which includes the idiopathic plasmacytic lymphadenopathy or IPL variant). First-line therapy for non-severe iMCD is siltuximab (anti-IL-6 monoclonal antibody, 11 mg/kg IV every 3 weeks) or tocilizumab; severe disease and TAFRO require combination siltuximab + high-dose corticosteroids. Refractory disease may require cytotoxic chemotherapy, rituximab, lenalidomide, sirolimus, or JAK inhibitors. Modern 5-year survival approaches 65-77 percent.

CDCN 2017
International consensus diagnostic criteria
IL-6
Driving cytokine; target of first-line therapy
TAFRO
Severe subtype requiring intensive therapy
~34%
Siltuximab response rate in pivotal RCT

S1. Castleman Disease Classification and Pathophysiology

Castleman Disease Classification

Castleman disease (CD) is a heterogeneous group of lymphoproliferative disorders unified by characteristic lymph node histology but diverse in etiology, clinical extent, and management. Modern classification by clinical extent and etiology:

CategoryFrequencyKey Features
Unicentric Castleman Disease (UCD)~75% of all CDSingle lymph node region; hyaline-vascular histology predominant; HHV-8 and HIV negative; surgically curable; excellent prognosis
HHV-8-associated MCDVariable (HIV epidemiology)Occurs in HIV-positive (most common) and other immunocompromised; lymph node LANA-1 positive; rituximab-based treatment
POEMS-associated MCD~10% of POEMSConcurrent with POEMS syndrome; managed as part of POEMS treatment
Idiopathic Multicentric Castleman Disease (iMCD)~10-20% of MCDHHV-8 negative HIV negative; CDCN 2017 criteria; subtypes TAFRO and NOS

iMCD Pathophysiology

The pathogenesis of iMCD is incompletely understood but appears to involve dysregulated immune response with cytokine storm, IL-6 being the dominant pathogenic cytokine in many patients. Three potential pathophysiologic models: IL-6 Cytokine Storm Cascade in iMCDVertical cascade showing IL-6 hypersecretion from lymph node germinal centers and plasma cells driving four downstream effector arms: B-cell and plasma-cell proliferation causing polyclonal hypergammaglobulinemia, hepatic acute-phase response causing CRP elevation, constitutional symptoms with organomegaly, and VEGF-mediated vascular leak causing effusions, with siltuximab and tocilizumab blocking the IL-6 axis.iMCD Pathophysiology: IL-6-Driven Cytokine StormLymph node germinal centers& plasma cells → IL-6 hypersecretionSiltuximab (anti-IL-6)Tocilizumab (anti-IL-6R)block the IL-6 axis hereB-cell / plasma-cellproliferationgerminal-center activationHepatic acute-phaseresponsehepcidin, fibrinogenConstitutional /organomegalyfever, hepatosplenomegalyVEGF inductionvascular leakeffusions, anasarcaPolyclonal hyper-gammaglobulinemiaCRP / ESR elevation,anemia (hepcidin)Weight loss, fatigue,night sweatsPleural / pericardialeffusion, ascitesPathophysiologic heterogeneity explains variable anti-IL-6 responseModel 1 IL-6-driven storm (responds to siltuximab) · Model 2 auto-inflammatory (IL-1, VEGF, IFN-γ)Model 3 autoimmune (may respond to rituximab) — only ~34% durable siltuximab response in the pivotal RCTIL-6 axisVEGF / vascular-leak armtherapeutic blockade pointMechanistic schematic of the dominant IL-6 model; a subset of iMCD is IL-6-independent and less anti-IL-6 responsive.

Model 1: IL-6-Driven Cytokine Storm

  • Excessive IL-6 production from lymph node germinal centers and plasma cells
  • IL-6 drives B cell proliferation, plasma cell differentiation, polyclonal hypergammaglobulinemia, acute phase response (CRP elevation)
  • IL-6 mediates constitutional symptoms (fever, fatigue, weight loss) and organomegaly
  • This subset responds to anti-IL-6 therapy (siltuximab, tocilizumab)

Model 2: Auto-Inflammatory Mechanism

  • Innate immune dysregulation independent of IL-6
  • Other cytokines including IL-1, VEGF, IL-10, IFN-gamma contribute
  • May respond less well to anti-IL-6 therapy
  • JAK inhibition (ruxolitinib) and other immunomodulators may be more effective

Model 3: Autoimmune Mechanism

  • Autoantibody-mediated pathology in subset of patients
  • Overlap with autoimmune lymphoproliferative syndromes
  • May respond to rituximab

The heterogeneity of underlying pathophysiology explains the variable response to anti-IL-6 therapy (approximately 34 percent durable response in the pivotal siltuximab trial) and the need for alternative therapeutic targets in refractory disease.

Clinical Features

Clinical FeatureFrequency in iMCD
Multicentric lymphadenopathyEssentially universal (defining feature)
Constitutional B-symptoms (fever, night sweats, weight loss)70-90%
Hepatosplenomegaly70-90%
CytopeniasAnemia 80%, thrombocytopenia 30-50% (more severe in TAFRO)
Effusions (pleural, pericardial, ascites)30-60% (more prominent in TAFRO)
Polyclonal hypergammaglobulinemia50-70% (less common in TAFRO)
Elevated CRP/ESREssentially universal
Eruptive cherry hemangiomas / violaceous papules10-30%
Renal dysfunction30-50% (often AA amyloidosis or thrombotic microangiopathy)
Hepatic dysfunction30-50%
Pulmonary involvement (LIP)10-20%

Epidemiology

  • Incidence: approximately 5-7 per million annually (all Castleman disease combined)
  • iMCD incidence: approximately 1-2 per million annually
  • Age: median diagnosis age 40-50 years, broader range than HHV-8 MCD
  • Sex: slight male predominance
  • HHV-8 status by definition negative
  • HIV status by definition negative

S2. CDCN 2017 iMCD Diagnostic Criteria

The CDCN 2017 Criteria Framework

The Castleman Disease Collaborative Network (CDCN) published international consensus diagnostic criteria in 2017 (Blood) that established the formal framework for iMCD diagnosis. All five components are required.

Required Diagnostic Components

1. Histopathology

Histopathologically confirmed Castleman disease on excisional lymph node biopsy, showing either:

  • Hyaline-vascular variant: regressed germinal centers (“burned out”), prominent vascular proliferation with sclerosis, onion-skin layering of mantle zones, atrophic dendritic cells
  • Plasma cell variant: hyperplastic germinal centers, sheets of plasma cells in interfollicular zones, preserved follicular architecture
  • Mixed variant: features of both

Fine needle aspiration is INADEQUATE; excisional biopsy is required.

2. Multicentric Distribution

Enlarged lymph nodes in at least 2 lymph node stations on imaging (CT or MRI of neck, chest, abdomen, pelvis):

  • Short-axis diameter >1 cm
  • At least 2 anatomically distinct regions (cervical, axillary, mediastinal, abdominal, pelvic, retroperitoneal)

3. Minor Criteria (At Least 2 of 11)

Must include at least 1 laboratory criterion AND at least 1 clinical criterion:

CategoryMinor Criterion
Laboratory (at least 1)Elevated CRP (>10 mg/L) or ESR (>15 mm/h)
Anemia (Hgb <12.5 g/dL men, <11.5 women)
Thrombocytopenia (platelets <150) OR thrombocytosis (>400)
Hypoalbuminemia (<3.5 g/dL)
Renal dysfunction (eGFR <60 mL/min) or proteinuria (>150 mg/24h)
Polyclonal hypergammaglobulinemia (total gamma globulin >1.7 g/dL)
Elevated alkaline phosphatase
Clinical (at least 1)Constitutional symptoms (night sweats, fever, weight loss, fatigue, hyperhidrosis)
Hepatomegaly and/or splenomegaly
Fluid accumulation (peripheral edema, ascites, pleural or pericardial effusion)
Eruptive cherry hemangiomatosis OR violaceous papules
Lymphocytic interstitial pneumonitis (LIP)

4. Exclusion of HHV-8 Infection

  • Lymph node LANA-1 immunohistochemistry NEGATIVE (LANA-1 = latent nuclear antigen-1, the gold standard marker of HHV-8 infection)
  • HHV-8 PCR may be supportive but LANA-1 IHC is the standard
  • HHV-8 positivity reclassifies the patient as HHV-8-associated MCD (different treatment paradigm)

5. Exclusion of Alternative Diagnoses

  • Infections: HIV, HHV-8, EBV, CMV, syphilis, TB, opportunistic infections
  • Autoimmune disease: SLE, juvenile idiopathic arthritis, autoimmune lymphoproliferative syndrome, IgG4-RD
  • Malignancy: lymphoma (Hodgkin, NHL), POEMS, multiple myeloma, follicular dendritic cell sarcoma, primary effusion lymphoma
  • POEMS syndrome: distinct entity; concurrent MCD reclassifies as POEMS-associated MCD
Pitfall — Castleman histology is not specific. The Castleman-like lymph node histology (hyaline-vascular or plasma cell variant) can occur as reactive finding in autoimmune disease, infection (especially HHV-8 even when LANA-1 IHC is borderline), POEMS syndrome, IgG4-related disease, and rarely lymphoma. The CDCN 2017 criteria explicitly require exclusion of alternative diagnoses because the histology alone is insufficient. Pursue a thorough workup including HHV-8 LANA-1 IHC, HIV testing, autoimmune serology, IgG4 IHC on lymph node, POEMS workup (serum VEGF, immunofixation, free light chains, skeletal survey), and lymphoma assessment with flow cytometry and PCR for clonality.

S3. TAFRO and NOS-IPL Subtypes

Two Major iMCD Subtypes

The CDCN 2017 criteria formalized two iMCD clinical subtypes that have substantially different presentations, treatment urgency, and prognosis: iMCD-TAFRO versus iMCD-NOS Subtype ComparisonEight paired horizontal bars diverging from a central axis: iMCD-TAFRO features extend left in danger red (acute severe onset, platelets often under 50000, prominent anasarca, normal or low gamma globulins, present reticulin fibrosis, frequent acute kidney injury, mild-moderate lymphadenopathy, siltuximab plus steroid first-line) and iMCD-NOS or IPL features extend right in accent green (subacute onset, variable platelets, less anasarca, high polyclonal hypergammaglobulinemia, less fibrosis, less renal involvement, prominent lymphadenopathy, siltuximab monotherapy).iMCD Subtypes: TAFRO vs NOS-IPL (CDCN 2017)iMCD-TAFRO (acute, severe)iMCD-NOS / IPL (subacute)Onsetacute, severesubacutePlateletssevere, often <50,000variableAnasarcaprominent (effusions, ascites)lessGamma globulinsNORMAL / LOWHIGH polyclonalBM fibrosispresent + megakaryocyteslessRenal (AKI)common, may be severeless commonLymphadenopathymild-moderateoften prominentFirst-line Rxsiltuximab + IV methylpredsiltuximab monotherapyTAFRO mimics TTP, primary myelofibrosis, autoimmune disease — excisional LN biopsy is required to confirm iMCDstrong TAFRO featureparadoxical / intermediatestrong NOS-IPL feature

FeatureiMCD-TAFROiMCD-NOS (including IPL)
OnsetAcute, severeSubacute to chronic
ThrombocytopeniaSevere (often <50,000)Variable, less severe
AnasarcaProminent (ascites, pleural/pericardial effusion, edema)Variable, less prominent
FeverHigh-grade, prolongedVariable
Reticulin fibrosis BMPresent with megakaryocyte hyperplasiaLess prominent
OrganomegalyProminentVariable
LymphadenopathyOften mild to moderateOften more prominent
HypergammaglobulinemiaNORMAL or LOW gamma globulins (paradoxical)Polyclonal hypergammaglobulinemia (frequent)
Renal dysfunctionCommon, may be severeLess prominent
Short-term mortality without treatmentSubstantialLower
First-line therapySiltuximab + high-dose corticosteroids; consider cytotoxic chemotherapy earlySiltuximab monotherapy or with steroids

TAFRO Subtype

TAFRO (Thrombocytopenia, Anasarca, Fever, Reticulin fibrosis, Organomegaly) was originally described in Japanese patients but is now recognized globally. Distinctive features:

  • Acute severe presentation: often hospitalized at diagnosis with multiple-organ involvement
  • Severe thrombocytopenia: platelets often <50,000, sometimes <30,000, with bleeding risk
  • Profound anasarca: bilateral pleural effusions, pericardial effusion, ascites, peripheral edema with associated hypoalbuminemia
  • Bone marrow shows reticulin fibrosis with megakaryocyte hyperplasia (often misinterpreted as primary myelofibrosis or MDS)
  • Hepatosplenomegaly common
  • Renal dysfunction: AKI, proteinuria, often requiring renal replacement therapy in severe cases
  • NORMAL or LOW gamma globulins: distinguishes from typical iMCD-NOS which has polyclonal hypergammaglobulinemia
  • Substantial short-term mortality without prompt treatment (20-30 percent in some series)

iMCD-NOS (Including IPL Variant)

iMCD-NOS (Not Otherwise Specified) encompasses iMCD that does not meet TAFRO criteria. A recognized subset is the idiopathic plasmacytic lymphadenopathy (IPL) variant characterized by:

  • Generalized lymphadenopathy with plasma cell histology
  • Marked polyclonal hypergammaglobulinemia (often gamma globulin >3-5 g/dL)
  • Anemia, often Coombs-positive
  • Less acute presentation than TAFRO
  • Better short-term prognosis but chronic course

Recognition of TAFRO — Why It Matters

Recognizing TAFRO at presentation is crucial because:

  • Treatment urgency differs: TAFRO requires immediate aggressive therapy (often hospitalization, ICU consideration)
  • Treatment intensity differs: TAFRO usually requires combination siltuximab + high-dose corticosteroids, with early consideration of cytotoxic chemotherapy
  • Prognosis differs: TAFRO has higher short-term mortality and lower response rate to anti-IL-6 monotherapy
  • Differential is different: TAFRO can mimic primary myelofibrosis (bone marrow reticulin fibrosis), TTP (thrombocytopenia + organ dysfunction), or autoimmune disease
Critical — TAFRO can mimic and delay diagnosis of TTP, primary myelofibrosis, autoimmune disease. TAFRO presents with thrombocytopenia, organ dysfunction, and constitutional symptoms that can be misdiagnosed as TTP (thrombocytopenia + renal dysfunction + neurologic features in some cases), primary myelofibrosis (bone marrow reticulin fibrosis), or systemic autoimmune disease. The diagnostic shift to TAFRO requires excisional lymph node biopsy showing Castleman histology plus HHV-8 negativity plus exclusion of alternatives. The treatment delay through these misdiagnoses can be catastrophic given TAFRO’s substantial short-term mortality.

S4. Histopathology and Differential Diagnosis

Histopathologic Variants

Hyaline-Vascular Variant (Predominant in UCD)

Histologic FeatureDescription
Regressed germinal centers“Burned out” appearance, atrophic, reduced cellularity
Onion-skin mantle zonesConcentric layering of mantle zone lymphocytes around regressed germinal center
Penetrating vesselsSclerosed hyalinized vessel penetrating into germinal center (“lollipop” appearance)
Dendritic cell prominenceCD21 and CD23 positive follicular dendritic cells
Twinning of germinal centersMultiple regressed germinal centers in single follicle
Interfollicular vascular proliferationHigh vascular density between follicles

Plasma Cell Variant (More Common in MCD)

Histologic FeatureDescription
Hyperplastic germinal centersEnlarged, active germinal centers (opposite of hyaline-vascular)
Plasma cell sheetsDiffuse plasma cells in interfollicular zones, often polytypic by light chain IHC
Preserved follicular architectureLess vascular proliferation than hyaline-vascular
Polyclonal natureLambda/kappa light chain ratio normal (excludes plasma cell neoplasm)

Mixed Variant

Combined features of hyaline-vascular and plasma cell variants; intermediate behavior.

Required Immunohistochemistry

IHC MarkerPurpose
HHV-8 LANA-1NEGATIVE in iMCD; positive reclassifies as HHV-8-associated MCD
CD20, CD3B and T cell distribution; rule out lymphoma
CD21, CD23Follicular dendritic cell network
Kappa/lambda light chainsPolyclonal in iMCD; monoclonal suggests plasma cell neoplasm or POEMS
IgG4Excludes IgG4-related disease (IgG4+ >10/HPF or IgG4/IgG >40%)
Ki-67Proliferation index; very high suggests aggressive lymphoma
CD138Plasma cell highlight

Differential Diagnosis

DifferentialDistinguishing Features
HHV-8-associated MCDHIV positive or immunocompromised; LANA-1 IHC positive; different treatment paradigm (rituximab + ART)
POEMS syndromePolyneuropathy, organomegaly, endocrinopathy, lambda M-protein, elevated VEGF, osteosclerotic lesions; ~10% of POEMS have concurrent MCD
IgG4-related diseaseStoriform fibrosis, IgG4+ plasma cells >10/HPF, IgG4/IgG >40%; elevated serum IgG4
Hodgkin lymphomaReed-Sternberg cells, CD30 and CD15 positive; clinical and histologic distinction usually clear
Non-Hodgkin lymphomaClonal lymphoproliferation; B-cell or T-cell receptor rearrangement by PCR; distinct histology
Angioimmunoblastic T-cell lymphoma (AITL)T follicular helper phenotype (CD4+ CD10+ PD-1+ BCL6+); arborizing high endothelial venules; can closely mimic Castleman
Plasmablastic lymphomaPlasmablastic morphology, HIV association, EBV positive, c-MYC rearrangement
Rosai-Dorfman diseaseSinus histiocytosis with massive lymphadenopathy; S100+ histiocytes with emperipolesis
Autoimmune lymphoproliferative syndrome (ALPS)FAS pathway mutations; double-negative T cells; family history
Primary myelofibrosis (TAFRO mimic)JAK2/CALR/MPL mutations; bone marrow histology distinct; no Castleman lymph nodes
TTP (TAFRO mimic)Microangiopathic hemolytic anemia, schistocytes, neurologic features, ADAMTS13 <10%
Systemic lupus erythematosusANA, anti-dsDNA, multi-system criteria-based diagnosis
Pearl — HHV-8 LANA-1 IHC is the single most important test. The HHV-8 status by LANA-1 immunohistochemistry on the lymph node biopsy is the single most important molecular test in Castleman disease workup because it fundamentally determines treatment paradigm: positive reclassifies as HHV-8-associated MCD treated with rituximab-based regimens (often combined with antiretroviral therapy in HIV); negative supports iMCD diagnosis treated with anti-IL-6 directed therapy. Always specifically request LANA-1 IHC on the lymph node specimen, not just HHV-8 PCR.
Pitfall — AITL closely mimics Castleman disease histology. Angioimmunoblastic T-cell lymphoma (AITL) has overlapping histologic features with Castleman disease including arborizing high endothelial venules, expanded follicular dendritic cell network, and B-cell hyperplasia. The clinical presentation can also overlap with lymphadenopathy, B-symptoms, hypergammaglobulinemia, and autoimmune phenomena. Distinguishing requires T-cell receptor clonality testing (PCR for TCR gamma rearrangement), T follicular helper marker IHC (CD4+ CD10+ PD-1+ BCL6+ CXCL13+), and expert hematopathology review. Missing AITL and treating as iMCD with anti-IL-6 therapy delays lymphoma-specific chemotherapy.

S5. Siltuximab, Tocilizumab, and Refractory Disease Management

CDCN Treatment Guidelines — First-Line

The Castleman Disease Collaborative Network treatment guidelines (Blood 2018) recommend risk-stratified first-line therapy based on disease severity:

Non-Severe iMCD (No Severe Organ Dysfunction, No TAFRO)

TherapyDoseComments
Siltuximab (preferred, FDA-approved)11 mg/kg IV every 3 weeksChimeric anti-IL-6 monoclonal antibody; van Rhee 2014 RCT: 34% durable response vs 0% placebo
Tocilizumab (alternative)8 mg/kg IV every 2 weeksAnti-IL-6 receptor antibody; standard of care in Japan; not FDA-approved for iMCD but widely used
Corticosteroids (adjunct)Prednisone 1 mg/kg PO daily, taperOften added for symptomatic relief during siltuximab response evaluation

Severe iMCD (Organ Dysfunction, TAFRO, Rapid Progression)

ComponentApproach
Siltuximab + high-dose corticosteroidsSiltuximab 11 mg/kg IV q3 weeks + methylprednisolone 1-2 mg/kg/day IV initially with gradual taper
Consider cytotoxic chemotherapy earlyR-CHOP, CHOP, or CVAD if rapid deterioration or organ failure
Supportive careICU monitoring if severe; platelet transfusion if active bleeding; renal replacement therapy for severe AKI; therapeutic thoracentesis/paracentesis for symptomatic effusions

Siltuximab Pivotal RCT Details

The van Rhee 2014 randomized placebo-controlled trial (Lancet Oncology) established siltuximab iMCD Treatment Outcomes and PrognosisLeft panel plots two outcome bar groups against a 0 to 100 percent axis: the van Rhee 2014 siltuximab pivotal trial durable response 34 percent versus 0 percent placebo, and modern 5-year survival 65 to 77 percent versus historical 50 to 60 percent. Right panel lists favorable prognostic factors in green (anti-IL-6 response, NOS subtype, age under 60, no organ dysfunction) and adverse factors in red (TAFRO subtype, hepatic and renal dysfunction, age over 60, severe thrombocytopenia, refractory disease).iMCD Treatment Outcomes & PrognosisResponse and Survival (%)255075100Siltuximab RCT34% durable responsePlacebo RCT0% (P<0.0001)5-yr survival(modern)65-77%5-yr survival(historical)50-60%First-line: siltuximab 11 mg/kg IV q3wkor tocilizumab 8 mg/kg IV q2wk;TAFRO / severe adds IV methylprednisoloneFavorable prognosis• Durable anti-IL-6 response• iMCD-NOS subtype• Age < 60 years• Non-severe presentation• No organ dysfunction• Preserved renal / hepatic fxAdverse prognosis• TAFRO subtype• Hepatic dysfunction• Renal dysfunction / AKI• Age > 60 years• Severe thrombocytopenia• Refractory disease• Concurrent paraneoplastic sxRefractory: RTX / CHOP / lenalidomide / sirolimus / ruxolitinibApproximate published ranges; not institutional outcome data. Response assessed at 3 and 6 months. ‘s role:

  • Design: 79 iMCD patients randomized 2:1 to siltuximab vs placebo, both with best supportive care
  • Primary endpoint: durable tumor and symptomatic response (combined improvement in lymph node, organomegaly, laboratory, and symptom measures)
  • Results: siltuximab 34 percent durable response vs 0 percent placebo (P<0.0001)
  • Safety: well tolerated; infections, pruritus, fatigue most common AEs
  • Approval: FDA approved 2014 specifically for iMCD; first-ever iMCD-specific approval

Tocilizumab Alternative

Tocilizumab (anti-IL-6 receptor antibody, rather than direct IL-6 neutralization like siltuximab) has been the standard of care for iMCD in Japan since 2005 based on the Nishimoto trial demonstrating clinical and laboratory improvement. Dosing 8 mg/kg IV every 2 weeks. Not FDA-approved for iMCD in the United States but widely used off-label internationally. Mechanism overlap with siltuximab makes them generally interchangeable for clinical purposes; choice is often determined by regional availability, cost, and physician familiarity.

Response Assessment

Response to anti-IL-6 therapy is assessed at 3 and 6 months using composite criteria:

  • Tumor response: lymph node size reduction, organomegaly regression
  • Laboratory response: normalization of CRP/ESR, hemoglobin improvement, albumin improvement, normalization of gamma globulins
  • Symptomatic response: resolution of constitutional symptoms, weight gain, functional improvement
  • Effusion resolution: ascites, pleural, pericardial effusion improvement

Refractory iMCD Management

For patients who fail to respond to anti-IL-6 therapy within 3-6 months or who progress on therapy, the CDCN treatment guidelines recommend:

Second-Line OptionDoseComments
Rituximab375 mg/m2 IV weekly x 4 weeksB-cell depletion; effective in some iMCD subsets (autoimmune-driven)
Cytotoxic combination chemotherapyR-CHOP, CHOP, or CVAD x 4-6 cyclesUsed for severe refractory disease or TAFRO with multi-organ failure
Lenalidomide25 mg PO daily on days 1-21 of 28-day cycleImmunomodulator; case series support; VTE prophylaxis required
Thalidomide100-400 mg PO dailyOlder immunomodulator; substantial neuropathy and VTE risk
Sirolimus (mTOR inhibitor)Trough-guided dosingTargets PI3K/AKT/mTOR pathway; case series and small trials suggest benefit, especially in refractory cases
Ruxolitinib (JAK inhibitor)15 mg PO BID typicalTargets JAK-STAT signaling downstream of IL-6 and other cytokines; emerging case series support, especially for refractory TAFRO
Hematopoietic stem cell transplantAutologous or allogeneicReserved for severe refractory disease; reported in case series

Unicentric Castleman Disease Management

Unicentric Castleman disease (UCD) management is fundamentally different from MCD and iMCD:

  • Complete surgical excision is the standard treatment, curative in approximately 90-95 percent of cases
  • Radiation therapy for unresectable lesions (e.g., extensive mediastinal disease)
  • Embolization may be considered for hypervascular lesions to reduce intraoperative bleeding
  • Anti-IL-6 therapy or rituximab rarely needed; reserved for symptomatic systemic disease in plasma cell variant UCD
  • Long-term surveillance: clinical follow-up; recurrence rare after complete excision

Long-Term Care and Surveillance

  • Periodic imaging: CT chest/abdomen/pelvis every 3-6 months during active treatment; every 6-12 months once stable
  • Laboratory monitoring: CBC, CMP, CRP, ESR, immunoglobulins; every 1-3 months during active treatment
  • Vaccination: avoid live vaccines during immunosuppression; consider hepatitis B vaccination given anti-IL-6 long-term use
  • Infection prophylaxis: consider Pneumocystis prophylaxis during prolonged corticosteroid use
  • Cancer surveillance: elevated risk of secondary lymphoma and other malignancies; routine age-appropriate screening
  • Pregnancy considerations: siltuximab and tocilizumab category B-C; counseling for women of reproductive age

S6. Practice Insights — Lessons from the Lymphoproliferative Disorders Clinic

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) After managing many iMCD patients across the lymphoproliferative disorders clinic over the past decade — including the dramatic TAFRO presentations admitted to ICU with severe thrombocytopenia and anasarca, and the more indolent NOS-IPL cases referred for years of unexplained lymphadenopathy and constitutional symptoms — clinicians have learned that the most consequential decisions are made at three points: pursuing excisional lymph node biopsy with comprehensive immunohistochemistry rather than accepting fine needle aspiration or core biopsy, recognizing TAFRO as a distinct urgent subtype requiring combination therapy rather than monotherapy, and engaging Castleman expert centers (CDCN-affiliated) for treatment planning given the rarity and complexity of management. In experienced hands, the patients who do worst are those whose TAFRO was misdiagnosed as TTP or primary myelofibrosis for weeks before the correct diagnosis, and those whose iMCD was treated empirically as lymphoma with R-CHOP without histopathologic confirmation.

1. Excisional lymph node biopsy mandatory — FNA and core biopsy inadequate

The single highest-yield diagnostic rule in experienced practice is that Castleman disease diagnosis REQUIRES excisional lymph node biopsy with comprehensive immunohistochemistry. Fine needle aspiration and core biopsy do not provide adequate architecture for Castleman histology recognition or for the IHC panel needed (HHV-8 LANA-1, CD20, CD21, CD23, kappa/lambda, IgG4, Ki-67). clinicians have seen multiple patients labeled with iMCD on core biopsy who proved to have angioimmunoblastic T-cell lymphoma, IgG4-RD, or POEMS-associated MCD when excisional biopsy was finally obtained. The standard now is to insist on excisional biopsy before committing to iMCD-directed therapy.

2. TAFRO requires combination siltuximab + steroids upfront, not monotherapy

In experienced hands, TAFRO patients started on siltuximab monotherapy without concurrent high-dose corticosteroids deteriorate over the weeks needed for siltuximab response evaluation. Experienced practice has shifted to initiating combination siltuximab + IV methylprednisolone 1-2 mg/kg/day at TAFRO diagnosis, with consideration of early cytotoxic chemotherapy (R-CHOP or CVAD) for patients with multi-organ failure or rapid progression. The combination upfront has reduced ICU mortality in the TAFRO experience substantially.

3. CDCN-affiliated expert center consultation for every iMCD diagnosis

iMCD is sufficiently rare that even academic hematologists see only occasional cases, and treatment selection benefits substantially from consultation with CDCN-affiliated expert centers (the Castleman Disease Collaborative Network maintains a list). Experienced practice is to engage CDCN expert consultation for every new iMCD diagnosis, particularly TAFRO cases and refractory disease. The expert centers offer access to clinical trials, second opinions on histopathology, and refined treatment algorithms developed from collective experience that no single non-specialty center can replicate.

4. POEMS workup in every iMCD — the overlap is meaningful

Approximately 10 percent of POEMS patients have concurrent MCD that meets Castleman histology criteria, and the management is fundamentally different (POEMS-directed therapy with lenalidomide-dexamethasone-ASCT rather than anti-IL-6). Experienced practice is to send serum and urine immunofixation, serum free light chains, serum VEGF, and skeletal survey or FDG-PET in every newly diagnosed iMCD to rule out concurrent or evolving POEMS. The lambda M-protein, elevated VEGF, and osteosclerotic lesions of POEMS reclassify the disease and change the entire treatment paradigm.

Illustrative Scenario —.(Composite teaching scenario assembled from published patterns; not an individual patient.) A woman in her late 40s presented to the emergency department with 2 weeks of progressive fatigue, abdominal distension, bilateral leg swelling, low-grade fever, and easy bruising. Examination revealed massive bilateral pleural effusions, ascites, hepatosplenomegaly, generalized lymphadenopathy, and petechiae on extremities. Laboratory studies showed Hgb 9.2, platelets 18,000 (severe thrombocytopenia), creatinine 2.4 (AKI), albumin 1.9 (hypoalbuminemia), AST/ALT 180/120, CRP 18 mg/dL, normal LDH, normal D-dimer (excluding TTP differential), ADAMTS13 activity 65 percent (normal). Initial workup focused on TTP and primary myelofibrosis. Bone marrow biopsy showed megakaryocyte hyperplasia with reticulin fibrosis grade 2 (initially raising primary myelofibrosis); JAK2/CALR/MPL mutations were negative. Excisional axillary lymph node biopsy showed mixed hyaline-vascular and plasma cell Castleman histology, HHV-8 LANA-1 IHC NEGATIVE, IgG4 panel negative, kappa/lambda polyclonal. HIV negative, HHV-8 PCR negative. POEMS workup including immunofixation, serum VEGF, and FDG-PET negative. The clinical constellation of severe Thrombocytopenia, Anasarca (bilateral pleural effusions + ascites + edema), Fever, Reticulin fibrosis of bone marrow, and Organomegaly (HSM) established iMCD-TAFRO diagnosis per CDCN 2017 criteria. She was started immediately on siltuximab 11 mg/kg IV plus IV methylprednisolone 2 mg/kg/day with ICU monitoring. After 2 doses of siltuximab she developed progressive organ dysfunction prompting addition of cyclophosphamide-based combination (CVAD). Over the subsequent 8 weeks her thrombocytopenia improved, anasarca resolved, renal function recovered, and CRP normalized. She was transitioned to maintenance siltuximab every 3 weeks with prednisone taper. At 18-month follow-up she remained in clinical remission on monthly siltuximab maintenance, with normal blood counts and resolution of imaging findings.
Four lessons compressed into one case: the TAFRO presentation initially raised TTP and primary myelofibrosis differentials, requiring excisional lymph node biopsy to establish the correct diagnosis; the HHV-8 LANA-1 IHC negativity and HIV negativity confirmed iMCD rather than HHV-8-associated MCD; the comprehensive POEMS workup ruled out the concurrent POEMS that would have changed the treatment paradigm; and the combination upfront therapy (siltuximab + IV methylprednisolone, escalating to CVAD when refractory) prevented the substantial mortality of untreated TAFRO.

Personal protocol adjustments beyond the published guideline

  • Excisional lymph node biopsy with comprehensive IHC mandatory, FNA/core biopsy inadequate. The guideline supports excisional biopsy; experienced practice formalizes this as a non-negotiable requirement before initiating iMCD-directed therapy, because architectural details and full IHC panel cannot be assessed on FNA or core biopsy.
  • Combination siltuximab + IV methylprednisolone upfront for TAFRO, not monotherapy. The CDCN guideline supports combination for severe disease; experienced practice formalizes combination as the standard initial regimen for all TAFRO patients, with early consideration of cytotoxic chemotherapy if multi-organ failure.
  • CDCN expert center consultation for every new iMCD diagnosis. The guideline encourages specialty consultation; experienced practice mandates it for every iMCD case, particularly TAFRO and refractory disease, because of the rarity and complexity of management.
  • POEMS workup (immunofixation, free light chains, VEGF, FDG-PET) in every newly diagnosed iMCD. The guideline notes POEMS overlap; experienced practice mandates the full POEMS workup at iMCD diagnosis because identifying concurrent POEMS reclassifies the disease and fundamentally changes treatment paradigm.
IMCD framework Four-panel visualization: Castleman classification tree, CDCN 2017 criteria checklist, TAFRO vs NOS subtype comparison grid, and treatment algorithm by severity and response. Personal iMCD Framework — Four Pillars 1. Castleman Disease Classification Castleman Disease UCD (~75%) MCD (~25%) HHV-8 MCD POEMS-MCD iMCD (~10-20% of MCD) HHV-8 negative + HIV negative 2. CDCN 2017 Criteria Checklist ✓ 1. Excisional LN biopsy: HV or PC histology ✓ 2. ≥2 enlarged LN stations (multicentric) ✓ 3. ≥2 of 11 minor criteria (lab + clinical) ✓ 4. HHV-8 LANA-1 IHC NEGATIVE ✓ 5. Exclude alternative dx (lymphoma, POEMS, IgG4) All 5 components required Histology + multicentric + minor + HHV-8 neg + exclusion 3. TAFRO vs NOS-IPL Subtypes Feature TAFRO NOS-IPL Onset Acute, severe Subacute Platelets Severe low Variable Anasarca Prominent Less Gamma globulins Normal/low HIGH polyclonal BM fibrosis Present Less Renal Often AKI Less common First-line Rx Sil+steroid Siltuximab TAFRO mimics TTP, MF, AD Excisional LN bx required 4. Treatment Algorithm iMCD confirmed (CDCN 2017) NON-SEVERE Siltuximab 11mg/kg q3wk ± prednisone TAFRO/SEVERE Siltuximab + IV methyl prednisone 1-2 mg/kg Refractory at 3-6mo? RTX / CHOP / Lena / Siro / Ruxo

Four-panel personal framework: the Castleman disease classification tree from UCD through MCD subtypes to iMCD (panel 1), the CDCN 2017 five-component diagnostic criteria checklist (panel 2), the TAFRO versus NOS-IPL subtype comparison grid with treatment paradigm differences (panel 3), and the severity-stratified treatment algorithm with refractory escalation pathway (panel 4). Approximate ranges; not institutional outcome data.

S7. Frequently Asked Questions

Q1. What is the Castleman disease classification framework?
Castleman disease is classified by clinical extent and etiology. Unicentric Castleman disease (UCD, 75 percent of all CD) involves a single lymph node region, often surgically curable, hyaline-vascular histology predominant, generally HHV-8 negative and HIV negative. Multicentric Castleman disease (MCD, 25 percent) involves multiple lymph node regions and is further subclassified: HHV-8-associated MCD (occurring in HIV-positive or other immunocompromised patients), POEMS-associated MCD (concurrent with POEMS syndrome), and idiopathic multicentric Castleman disease (iMCD, HHV-8-negative HIV-negative, the most clinically challenging form). The CDCN (Castleman Disease Collaborative Network) 2017 international consensus criteria formalized iMCD subtypes: iMCD-TAFRO (distinctive clinical syndrome) and iMCD-NOS (not otherwise specified, includes idiopathic plasmacytic lymphadenopathy or IPL variant).
Q2. What are the CDCN 2017 diagnostic criteria for iMCD?
The CDCN 2017 international consensus criteria for iMCD diagnosis require all of: (1) histopathologically confirmed Castleman disease (hyaline-vascular or plasma cell variant) on excisional lymph node biopsy; (2) at least 2 enlarged lymph node stations (multicentric distribution); (3) at least 2 of 11 minor criteria including 1 laboratory abnormality (elevated CRP/ESR, anemia, thrombocytopenia or thrombocytosis, hypoalbuminemia, polyclonal hypergammaglobulinemia, elevated creatinine, elevated alkaline phosphatase) and 1 clinical criterion (constitutional symptoms, splenomegaly or hepatomegaly, fluid accumulation, eruptive cherry hemangiomatosis or violaceous papules, lymphocytic interstitial pneumonitis); (4) exclusion of HHV-8 infection (LANA-1 negative on lymph node IHC); (5) exclusion of alternative diagnoses (lymphoma, autoimmune disease, infection).
Q3. What is TAFRO syndrome?
TAFRO is a distinct iMCD subtype defined by the constellation of Thrombocytopenia (often severe with platelets less than 100,000), Anasarca (ascites, pleural effusion, pericardial effusion, peripheral edema), Fever (high-grade with constitutional symptoms), Reticulin fibrosis of bone marrow with megakaryocyte hyperplasia, and Organomegaly (hepatosplenomegaly). TAFRO syndrome was originally described in Japanese patients but is now recognized globally. Compared to iMCD-NOS, TAFRO has more severe acute presentation, more profound thrombocytopenia, more prominent anasarca, normal or low gamma globulins (rather than hypergammaglobulinemia), and worse short-term prognosis without prompt treatment. TAFRO requires more intensive initial therapy (often combination siltuximab + corticosteroids, with consideration of cytotoxic chemotherapy for severe disease) than typical iMCD-NOS.
Q4. How does iMCD differ from HHV-8-associated MCD?
HHV-8-associated MCD occurs in HIV-positive patients (most commonly) and other immunocompromised individuals; lymph node tissue shows HHV-8 latent nuclear antigen-1 (LANA-1) positive cells in the mantle zone; pathogenesis involves HHV-8 viral homolog of IL-6 (vIL-6) plus other viral cytokines driving inflammation; treatment is rituximab-based (often combined with antiretroviral therapy in HIV) with high response rates. iMCD by definition is HHV-8-negative HIV-negative; pathogenesis involves IL-6 driven inflammation (in most patients), VEGF, and other cytokines; treatment is anti-IL-6 directed (siltuximab first-line); response rates lower than HHV-8 MCD; some patients have iMCD that is not IL-6 driven and responds less well to anti-IL-6 therapy. The HHV-8 status determines fundamental treatment selection.
Q5. What is the role of siltuximab in iMCD treatment?
Siltuximab is a chimeric monoclonal antibody directly binding and neutralizing IL-6 (distinct from tocilizumab which targets the IL-6 receptor). Siltuximab is the only FDA-approved treatment specifically for iMCD based on the pivotal randomized controlled trial (van Rhee, 2014) demonstrating 34 percent durable tumor and symptomatic response versus 0 percent in placebo. Standard dosing is siltuximab 11 mg/kg IV every 3 weeks, with continuation as long as benefit and tolerability. Response is typically gradual over months. Tocilizumab is an alternative (used in Japan as standard of care for iMCD before siltuximab FDA approval) dosed at 8 mg/kg IV every 2 weeks. Both are first-line for newly diagnosed non-severe iMCD per CDCN treatment guidelines.
Q6. How is severe or refractory iMCD treated?
For severe iMCD (TAFRO subtype, severe inflammation, organ dysfunction, life-threatening cytopenias) or rapidly progressive disease, the CDCN treatment guidelines recommend combination siltuximab plus high-dose corticosteroids (methylprednisolone 1-2 mg/kg/day) as first-line. For refractory disease (failure to respond to anti-IL-6 within 3-6 months), options include cytotoxic combination chemotherapy (R-CHOP, CHOP, CVAD), rituximab, immunomodulators (lenalidomide, thalidomide), mTOR inhibitors (sirolimus), and JAK inhibitors (ruxolitinib). The choice depends on disease severity, patient comorbidities, and previous responses. For refractory TAFRO, cytotoxic chemotherapy is more commonly required and earlier in the treatment sequence than for iMCD-NOS. Hematopoietic stem cell transplant has been reported in case series for severe refractory disease.
Q7. What is unicentric Castleman disease and how is it managed?
Unicentric Castleman disease (UCD) is a single-region lymphadenopathy that accounts for approximately 75 percent of all Castleman disease cases. Hyaline-vascular histology predominates (90 percent), with characteristic onion-skin appearance of mantle zones around regressed germinal centers and prominent vascular proliferation. UCD is HHV-8 negative and HIV negative by definition. Most patients are asymptomatic with isolated lymphadenopathy discovered incidentally; some develop systemic symptoms in plasma cell variant UCD or paraneoplastic syndromes (paraneoplastic pemphigus, paraneoplastic neurologic syndromes). Treatment is complete surgical excision, which is curative in approximately 90-95 percent of cases. Radiation therapy is an alternative for unresectable cases. Systemic therapy (anti-IL-6, rituximab) is rarely needed. Long-term prognosis after curative resection is excellent.
Q8. What is the long-term prognosis of iMCD?
iMCD prognosis varies widely by subtype, severity, and treatment response. Overall 5-year survival is approximately 65-77 percent with modern treatment, substantially improved from historical 50-60 percent. Favorable prognostic factors include response to anti-IL-6 therapy, iMCD-NOS subtype, age less than 60, less severe initial presentation, and absence of organ dysfunction. Adverse prognostic factors include TAFRO subtype, hepatic dysfunction, renal dysfunction, age over 60, severe thrombocytopenia, refractory disease, and concurrent paraneoplastic syndromes. Treatment-related adverse events from prolonged anti-IL-6 therapy include infection risk, hepatic enzyme elevation, and rare hypersensitivity reactions; long-term safety is generally favorable. Lifelong hematology follow-up is required with periodic imaging, laboratory monitoring, and disease activity assessment.
↑

Leave a Reply

Your email address will not be published. Required fields are marked *